Detalles de la búsqueda
1.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
N Engl J Med
; 386(4): 305-315, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34937145
2.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Clin Infect Dis
; 76(4): 720-729, 2023 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35235656
3.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clin Infect Dis
; 75(6): 975-986, 2022 09 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35079789
4.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis
; 71(8): 1920-1929, 2020 11 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31905383
5.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
J Acquir Immune Defic Syndr
; 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346427
6.
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Lancet HIV
; 2024 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38734016
7.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Lancet HIV
; 10(9): e566-e577, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37567205
8.
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
Open Forum Infect Dis
; 9(5): ofac104, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35493119
9.
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
AIDS
; 36(2): 195-203, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34652287
10.
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
AIDS
; 36(3): 373-382, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34750291
11.
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
J Acquir Immune Defic Syndr
; 88(1): 86-95, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34397746
12.
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Antivir Ther
; 24(6): 425-435, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355775
13.
Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.
Infect Dis Ther
; 7(1): 147-159, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29335895
14.
Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
J Acquir Immune Defic Syndr
; 73(3): 268-274, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27159225
15.
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
J Acquir Immune Defic Syndr
; 71(5): 538-43, 2016 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26605505
16.
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Lancet HIV
; 3(1): e13-22, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26762988
17.
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Lancet HIV
; 3(4): e158-65, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27036991
18.
Antibiotic susceptibilities of bacteria isolated within the oral flora of Florida blacktip sharks: guidance for empiric antibiotic therapy.
PLoS One
; 9(8): e104577, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25110948
19.
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
J Int AIDS Soc
; 17(4 Suppl 3): 19532, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25394041
20.
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
AIDS Res Hum Retroviruses
; 29(10): 1287-92, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23782005